Lundbeck is focused on the global launch of its new migraine therapy Vyepti in the coming years, and the development of additional indications, as its reported a 4% increase in revenues in 2020 which were within its pre-pandemic guidance.
H. Lundbeck A/S achieved a lot in 2020 with its newest product, the migraine preventive therapy, Vyepti (eptinezumab-jjmr), administered by quarterly intravenous infusion, despite the COVID-19 pandemic, reported company president and CEO Deborah Dunsire.
Achievements with Vyepti included its approval in another two markets, Canada and the United Arab Emirates (UAE), and the acceptance...
Swiss major confident that new oncology drugs will fill revenue gap.
Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.
Bharatt Chowrira departs days after firm’s chair stepped down.
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
